Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile

Clostridium difficile Infection and Fecal Microbiota Transplant.

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent C...

Fecal Microbiota Transplantation (FMT) for Recurrent/Refractory Clostridium difficile Infection (CDI) in Pediatric Immunocompromised Patients: A Single-center Experience

Weight Changes in Fecal Microbiota Transplant for Clostridium difficile

Fecal microbiota transplant protocol for clostridium difficile infection.

Fecal microbiota transplant has become more acceptable as a therapeutic for recurrent Clostridium difficile infection. The FDA has an enforcement discretion policy for practitioner's performing this therapy, which includes informed consent for this experimental treatment. This manuscript describes a typical procedure that can be followed that includes the important aspects of this preparation a...

Fecal microbiota transplant in immunocompromised patients: Encouraging results in a vulnarable population.

Definitely, fecal microbiota transplantation (FMT) is a promising research area in disorders with dysbiosis. It is not a novel therapy, however recent advances in gut microbiota research enabled physicians to practice FMT in a more scientific basis. One of the main drawbacks in FMT is the safety and adverse events, which are not thoroughly documented in large series. Among these, immunocompromi...